I am a Biotech founder and executive with 14+ years of drug discovery and development experience gained at big pharma and start-up. I started my career at GSK where I conducted clinical development in Oncology. I was a translational medicine lead and was a core team member to bring three drugs to the market – Tafinlar, Mekinist and Blenrep. Additionally, I led the development of GSK’s first companion diagnostic assay. I later founded Chimeron Bio, a leading-edge RNA biotech based in Philadelphia, and led the company as its CEO from 2017-2022. Under my leadership, Chimeron developed a novel RNA platform for applications in Oncology, Infectious Diseases and Rare Gene Disorders. Currently, I am building Able Sciences, where we are applying RNA to engineer immune cells towards potent and broad-spectrum cell therapies.
I obtained my Ph.D. at the University of Georgia and conducted my post-doctoral training at the University of Pennsylvania. I hold an M.B.A. from the Columbia Business School.